FDA批准Hydros前列腺治疗，程序跳跃

2024-08-21 22:42

Shares of PROCEPT BioRobotics (NASDAQ:PRCT) gained on Wednesday morning after the surgical robotics company announced the FDA clearance of its HYDROS Robotic System as a therapy for benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate gland.
The San Jose, California-based medical device company said that the FDA issued the AI-powered platform the agency's 510(k) clearance, paving the way for its U.S. launch.
HYDROS Robotic System is designed to deliver aquablation therapy for BPH using real-time ultrasound imaging and cystoscopy data.
With a multidimensional view of the prostate, surgeons can provide patients with a personalized treatment option to provide relief without impacting their sexual function or continence.
Despite its intentions to begin a full-market release of HYDROS in the current quarter, the company reiterated its previously issued financial guidance for the year.

More on Procept